Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia

Kornblau, Steven M.; McCue, David; Singh, Navjot; Chen, Wenjing; Estrov, Zeev; Coombes, Kevin R.

doi:10.1182/blood-2010-01-262071

Cited by 144 publications

(169 citation statements)

References 46 publications

Supporting

Mentioning

155

Contrasting

Order By: Relevance

“…36 Although we are unable to draw mechanistic conclusions, we observed that patients exposed to this regimen experienced significant increas in specific bone marrow cytokines, including those involved in differentiation (macrophage colony-stimulating factor and granulocyte colony-stimulating factor) and hematopoiesis stem cell factor. In patients who received induction chemotherapy, high expression of macrophage colony-stimulating factor-receptor and granulocyte colony-stimulating factor-receptor and low expression of stem cell factor-receptor have been shown to correlate with a better prognosis.…”

Section: Discussionmentioning

confidence: 63%

Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia

et al. 2011

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) is a disease of the elderly. Poor outcomes with standard therapies necessitate novel approaches. Outpatient regimens sufficiently potent and well tolerated to induce remissions and enable continuation therapy may be beneficial. In this phase-1 study, we determined the maximum tolerated dose (MTD) and the efficacy for sequential azacitidine and lenalidomide as remission induction and continuation therapy in elderly, previously untreated patients. We investigated the impact on global DNA methylation and bone marrow cytokines, and sought biological predictors of response. Eighteen patients were enrolled. The MTD was not reached. Median follow-up was 8.2 months (10.3 months for survivors). Common adverse events included fatigue, injection site reactions, constipation, nausea, pruritus and febrile neutropenia. Ten patients responded (56%), and the rate of complete remissions (CRs) or CRs with incomplete recovery of blood counts for evaluable patients was 44% (7/16). The median response duration was 6.2 months. DNA demethylation and changes in bone marrow cytokines were observed; responders had a unique cytokine profile and a trend towards lower methylation levels. Sequential azacitidine and lenalidomide was well tolerated with encouraging clinical and biological activity in previously untreated elderly AML patients. This trial is registered at ClinicalTrials.gov (NCT00890929).

show abstract

Section: Discussionmentioning

confidence: 63%

Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia

et al. 2011

View full text Add to dashboard Cite

show abstract

“…9 Previous reports showed that serum levels of inflammatory cytokines or chemokines in AML patients may represent a prognostic factor and correlate with the clinical outcome. 10,11 In this context, we have previously shown that IL-8 may accelerate in vitro CD34 + cell differentiation towards CD161 + CD56 + (NK) cells, thus suggesting that cytokines or chemokines, released during an inflammatory process, may influence NK-cell differentiation. 4 In the present study, in order to address the question as to whether AML blasts may affect NK-cell development, we performed co-cultures of umbilical cord blood (UCB)-CD34 + cells in the absence [control (CTR)] or in the presence of fresh leukemia blasts belonging to different FAB categories.…”

Section: -5mentioning

confidence: 99%

IL-1 -releasing human acute myeloid leukemia blasts modulate natural killer cell differentiation from CD34+ precursors

et al. 2014

View full text Add to dashboard Cite

“…The knowledge gained from multi-analytical determination of cytokines and adhesion molecules could allow better diagnosis and management of hematological malignancies, since cytokines or their receptors may also represent a target for specific anticancer therapy at the molecular level. Recently, some studies reported the possible diagnostic and prognostic use of cytokine levels in newly diagnosed AML and myelodysplastic syndromes [7][8][9] .…”

Section: Introductionmentioning

confidence: 99%

Multi-analytical evaluation of serum levels of cytokines and adhesion molecules in patients treated for acute myeloid leukemia using biochip array technology

Horáček¹,

Vašatová²,

Kupsa³

et al. 2013

BIOMED PAP

View full text Add to dashboard Cite

Aims. Evaluation of serum levels of 17 cytokines and 5 adhesion molecules in patients treated for acute myeloid leukemia (AML) using biochip array technology. This approach allows multi-analytical determination from a single sample. Methods. A total of 15 AML patients were studied. Blood samples were taken at the diagnosis (active leukemia) and at circa 6 months after completion of last chemotherapy (durable complete remission in all patients).Results. Comparing cytokine and adhesion molecule levels in active leukemia and in durable complete remission, we found significant increase (P<0.01) in serum interleukin-7 (IL-7), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), and significant decrease (P<0.01) in serum E-selectin. Discussion. Our results indicate that serum levels of specific cytokines and adhesion molecules (IL-7, EGF, VEGF, E-selectin) are significantly altered in patients treated for AML, reflecting activity of the disease. Further investigation is needed to establish if the changes observed in the levels of these molecules could be used as a prognostic indicator of AML.

show abstract

Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia

Cited by 144 publications

References 46 publications

Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia

Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia

IL-1 -releasing human acute myeloid leukemia blasts modulate natural killer cell differentiation from CD34+ precursors

Multi-analytical evaluation of serum levels of cytokines and adhesion molecules in patients treated for acute myeloid leukemia using biochip array technology

Contact Info

Product

Resources

About